famotidine has been researched along with Breast Cancer in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 9.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
| "Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 5.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
| "Paclitaxel-based chemotherapy continues to be an integral component of breast cancer treatment." | 3.81 | Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. ( Berger, MJ; Layman, R; Lustberg, MB; Macrae, E; Mrozek, E; Phillips, G; Ramaswamy, B; Shapiro, CL; Shaver, K; Vargo, C; Vincent, M; Wesolowski, R, 2015) |
| "Current use of H(2) blockers overall, cimetidine, and famotidine was not associated with an increased risk of either invasive ductal or invasive lobular breast cancer." | 3.74 | Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. ( Daling, JR; Li, CI; Malone, KE; Mathes, RW; Porter, PL, 2008) |
| "Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer." | 1.37 | Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey. ( Aogi, K; Ishiguro, H; Iwata, H; Kawaguchi, K; Kuroi, K; Masuda, N; Morita, S; Nakamura, S; Ohno, S; Toi, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, MJ | 1 |
| Vargo, C | 1 |
| Vincent, M | 1 |
| Shaver, K | 1 |
| Phillips, G | 1 |
| Layman, R | 1 |
| Macrae, E | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Wesolowski, R | 1 |
| Shapiro, CL | 1 |
| Lustberg, MB | 1 |
| Kawaguchi, K | 1 |
| Ishiguro, H | 1 |
| Morita, S | 1 |
| Nakamura, S | 1 |
| Ohno, S | 1 |
| Masuda, N | 1 |
| Iwata, H | 1 |
| Aogi, K | 1 |
| Kuroi, K | 1 |
| Toi, M | 1 |
| Parshad, R | 1 |
| Kapoor, S | 1 |
| Gupta, SD | 1 |
| Kumar, A | 1 |
| Chattopadhyaya, TK | 1 |
| Mathes, RW | 1 |
| Malone, KE | 1 |
| Daling, JR | 1 |
| Porter, PL | 1 |
| Li, CI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel[NCT04237090] | Phase 3 | 27 participants (Actual) | Interventional | 2020-02-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for famotidine and Breast Cancer
| Article | Year |
|---|---|
Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Case-Control Studies; F | 2002 |
3 other studies available for famotidine and Breast Cancer
| Article | Year |
|---|---|
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2015 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Topics: Acetamides; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Erythema; Famotidine | 2011 |
Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer.
Topics: Aged; Anti-Ulcer Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Contr | 2008 |